Roche (Basel, Switzerland) said that it is proposing to acquire all outstanding shares of Illumina (San Diego) for $44.50 per share in cash, or about $5.7 billion on a fully diluted basis, in what could be the biggest deal in med-tech this year if it happens. If the acquisition is successful, then Roche could take a leading position in the emerging field of DNA sequencing. Read More
